Bishoy M. Faltas, MD, discusses the current use of genomic testing to guide urothelial cancer treatment.
Bishoy M. Faltas, MD, assistant professor of Medicine and assistant attending for the Genitourinary Oncology Program in the Division of Hematology & Medical Oncology at Weil Cornell Medicine, discusses the current use of genomic testing to guide urothelial cancer (UC) treatment.
With each year, the role of genomic testing is playing an increasingly important role in UC. Several actionable mutations include FGFR3, PIK3CA, and CDKN2A.
There are several different options for genomic testing in bladder cancer patients. Commercial panels are available in the community setting, while in the academic setting, there is access to tools that provide a more comprehensive view of the genome.
Understanding the differences between the tests, the differences between a research grade and a clinical grade test or assay, and how to interpret the meaning of the test are most important for those practicing genomic testing in these settings, according to Faltas.
Transcription:
0:08 | We've been learning a lot over the past few years about the genomic underpinnings of bladder cancer. The role of genomic testing is expanding almost every year as we learn more about the role of genomic alterations in the pathogenesis, the natural history, and response to treatment in patients with bladder cancer. This year, we are learning a lot more about the role of the germline variants in urothelial cancer. Germline variants are these alterations that we're all born with, that are inherited.
0:54 | This year, we published a manuscript in Nature Communications that looked at the role of germline alterations or germline variants, in bladder cancer patients. We identified several common germline variants in these patients, which is consistent with other findings that are emerging from other groups. Now, we're trying to understand how these germline alterations interact with the cancer, somatic alterations to shape the course of bladder cancer.
Responders to UGN-101 Have Positive RFS in Upper Tract Urothelial Cancer
May 5th 2024In patients at 15 centers who had upper tract urothelial cancer, those with no evidence of disease after UGN-101 induction had a 68% rate of 3-year recurrence-free survival, and this outcome did not differ based on tumor status, method of instillation, or treatment intent.
Read More
UGN-101 Shows Promise for Upper Tract Urothelial Cancer Durability
May 5th 2024Maintenance UGN-101 therapy demonstrated good durability of response in initial responders with low-grade upper tract urothelial cancer, as evidenced by a low rate of disease progression in a multicenter, longitudinal follow-up study.
Read More
Nivolumab With Gemcitabine-Cisplatin Boosts Survival in Metastatic Urothelial Carcinoma
May 5th 2024Combination therapy with nivolumab and gemcitabine-cisplatin showed promising results in treating metastatic urothelial carcinoma with significantly improved overall survival and progression-free survival rates.
Read More